This is a summary of the European public assessment report (EPAR) for Entacapone Orion. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Entacapone Orion.
Therapeutic Indication
### Therapeutic indication Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.
Therapeutic Area (MeSH)
ATC Code
N04BX02
ATC Item
entacapone
Pharmacotherapeutic Group
Anti-Parkinson drugs
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| entacapone | N/A | 恩他卡朋 |
EMA Name
Entacapone Orion
Medicine Name
Entacapone Orion
Aliases
N/ANo risk management plan link.
